同步放化疗与度伐利尤单抗引起的治疗相关肺部不良事件影响局部晚期非小细胞肺癌生存
该研究分析了2010年7月至2019年11月间326例局部晚期非小细胞肺癌患者,其中195例接受同步放化疗(CRT),131例接受同步放化疗后度伐利尤单抗免疫治疗(CRTI)。CRTI组症状性治疗相关肺部不良事件(TRPAE)发生率几乎翻倍(65.7% vs 35.9%,P<0.0001),但≥3级TRPAE两组相似。度伐利尤单抗与更好的4年总生存(OS)和无进展生存(PFS)相关,因TRPAE中断免疫治疗者生存更差。
要点
- CRTI组症状性TRPAE发生率为65.7%,显著高于CRT组的35.9%(P<0.0001)。
- 度伐利尤单抗组4年OS为54.5% vs 36.7%(P=0.0003),4年PFS为43.8% vs 35.8%(P=0.038)。
- 因TRPAE中断免疫治疗者4年OS更差(P=0.001),远处转移率更高(P=0.003)。
核心结论
- 同步放化疗后辅助免疫检查点抑制剂(ICI)可改善4年OS和PFS,与已发表数据一致。
- CRTI与更高的≥2级TRPAE发生率相关,在高和低平均肺剂量组中均如此,但≥3级TRPAE无显著差异。
- 因TRPAE中断ICI与更差的OS和远处疾病控制相关,相比发生TRPAE后按计划完成ICI者。
研究设计与样本
- 研究分析了2010年7月至2019年11月间治疗的326例局部晚期非小细胞肺癌患者,其中195例接受CRT,131例接受CRTI。
- TRPAE定义为放疗完成后12个月内发生的任何符合CTCAE v.5定义的肺部事件。
- 采用Cox比例风险回归和Kaplan-Meier分析比较CRT与CRTI的结局,并评估TRPAE导致的ICI中断是否影响生存。
主要发现
- CRTI组症状性TRPAE发生率为65.7%,CRT组为35.9%(P<0.0001)。
- CRT+度伐利尤单抗组与CRT组的4年OS分别为54.5%和36.7%(P=0.0003),4年PFS分别为43.8%和35.8%(P=0.038)。
- 接受度伐利尤单抗与更好的4年OS相关(HR 0.53,95%CI 0.36-0.78,P=0.001)和更好的4年PFS相关(HR 0.55,95%CI 0.38-0.80,P=0.002)。
- 因TRPAE中断ICI的患者相比发生TRPAE后按计划完成ICI者,4年OS更差(P=0.001),远处转移率更高(P=0.003)。
关键数值与推荐
- TRPAE定义:放疗完成后12个月内发生的任何符合CTCAE v.5定义的肺部事件。
- 严重TRPAE定义为≥3级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We compared treatment-related pulmonary adverse events (TRPAE), progression-free survival (PFS), and overall survival (OS) among locally advanced non-small cell lung cancer (NSCLC) patients who received concurrent chemoradiotherapy (CRT) versus CRT followed by immune check point inhibitor (ICI) immunotherapy (CRTI). MATERIALS AND METHODS: TRPAE was defined as any pulmonary events as defined in CTCAE v.5 occurring within 12 months after completion of radiotherapy. Outcomes were compared between CRT and CTRI by Cox proportional hazard regression and Kaplan-Meier analyses. We also assessed if TRPAE-induced discontinuation of ICI affected survival. RESULTS: We analyzed 326 patients treated between July 2010 and November 2019; 195 patients received CRT and 131 received CRTI. The incidences of severe grade ≥ 3 TRPAE were similar between the two groups, however, symptomatic TRPAE was almost doubled in CRTI group (65.7 % CTRI vs 35.9 % CRT, P < 0.0001). The rates of 4-year OS and PFS were 54.5 % vs 36.7 % (P = 0.0003) and 43.8 % vs 35.8 % (P = 0.038) in CRT + Durvalumab and CRT group, respectively. Receipt of ICI Durvalumab was associated with better 4-year OS (HR 0.53, 95 % CI 0.36-0.78, P = 0.001) and PFS (HR 0.55, 95 % CI 0.38-0.80, P = 0.002). Patients who discontinued ICI because of TRPAE had worse 4-year OS (P = 0.001) and higher rates of distant metastasis (P = 0.003) than those who completed planned ICI after developing TRPAE. CONCLUSION: CRT followed by adjuvant ICI led to improved 4-year OS and PFS consistent with published data. CRTI was associated with higher incidence of grade ≥ 2 TRPAE in both high and low mean lung dose groups without significant difference in grade ≥ 3 TRPAE. Discontinuation of ICI due to TRPAE was associated with poorer OS and distant disease control than completing ICI as planned after developing TRPAE.
引用
- Xu T, Wu L, Gandhi S, et al. Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer. Radiother Oncol. 2022. PMID: 36209942. doi:10.1016/j.radonc.2022.10.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。